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2012.10.0Abstract Background and Aim: The pathological diagnosis of papillary thyroid carcinoma (PTC)
is usually easily achieved. However distinguishing the follicular variant of papillary carcinoma
(FVPC) from other follicular thyroid lesions is an area of controversy. In this study we investigated
the role of CD56 and claudin-1 in the discriminating the FVPCs from other solitary follicular pat-
terned nodules. We also evaluated the application of these two markers in reclassifying the contro-
versial cases of the well differentiated tumors of unknown malignant potential (WDTs-UMP).
Materials and methods: The immunohistochemical expression of CD56 and claudin-1 was evalu-
ated in 86 samples of thyroid lesions together with 10 samples of normal thyroid tissue. Thyroid
lesions included: 29 PTCs [classic papillary carcinoma (n= 13) and FVPC (n= 16)], 47 solitary fol-
licular patterned nodules [follicular adenomas (n= 12), hyperplastic nodules (n= 32) and follicu-
lar tumor of unknown malignant potential (n= 3)] and 10 WDTs-UMP.
Results: The statistical analysis showed signiﬁcantly different expressions of each of CD56 and
claudin-1 in the FVPCs versus other solitary follicular patterned nodules. Claudin-1 sensitivity
(100%) was higher than CD56 sensitivity (81.3%). However claudin-1 speciﬁcity (80.9%) was <
CD56 speciﬁcity (89.4%). The combined use of CD56 and claudin-1(claudin-1+/CD56) showedcarcinoma; FVPC, follicular
MP, well differentiated tumor
-UMP, follicular tumor of
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176 R.M. Abd El Atti, L.S. Shashspeciﬁcity (100%), positive predictive value (100%) and sensitivity (81.3%) in the differentiation
between the FVPCs and other follicular nodules. In the light of this statistical outcome, 5/10 cases
of WDTs-UMP expressing the (claudin-1+/CD56) panel could be rediagnosed as PTC.
Conclusion: Combined utility of CD56 and claudin-1 is helpful in diagnosing the FVPC and its dif-
ferentiation from other follicular patterned nodules. Application of these two markers may greatly
aid in the reevaluation of the WDTs-UMP and interpretation of their expected behavior.
ª 2012 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.Introduction
Papillary thyroid carcinoma (PTC) is the most common type
of thyroid cancer comprising approximately 80% of thyroid
epithelial malignancies [1,2].
The ‘‘gold standard’’ in diagnosis of thyroid nodules is path-
ologic evaluation using routine hematoxylin and eosin (H&E)
staining. However, morphologic overlap between follicular le-
sions especially the follicular variant of papillary carcinoma
(FVPC) is common. In such cases an objective consistent diag-
nosis based merely on morphologic assessment is sometimes
impossible [3].
Consequently, immunohistochemical and molecular meth-
ods were investigated to aid in the diagnosis of these problem-
atic cases [4–7]. Several immunohistochemical markers such as
galectin-3, cytokeratin-19 and HBME-1 have been recom-
mended to help in the discrimination between these controver-
sial thyroid nodules [8]. Nonetheless up till now there is no
agreed consensus about an immunohistochemical panel that
would reliably overcome such diagnostic obstacles.
Claudin-1, a member of claudin family, is identiﬁed as a
tight junction component [9]. Tight junctions are transmem-
brane and cytoplasmic proteins which mainly prevent the free
diffusion of solutes and maintain cell polarity [10,11]. Increased
claudin-1 expression has been reported in PTC [12,13]. On the
other hand, CD56, a neural cell adhesion molecule (NCAM)
[14], has been reported to be expressed in normal thyroid follic-
ular cells with frequent low expression in malignant thyroid tu-
mors especially PTC [15–18]. CD56 regulates cell motility and
hemophilic binding between neurons, hence its expression
may affect the migratory capacity of tumor cells [19].
Claudin-1 and CD56 have been candidates for investiga-
tions in several studies for the diagnosis of PTC. However
none of these studies, to the best of our knowledge, applied
the combination of both claudin-1 and CD56 in an immuno-
histochemical panel to test the probability of an additive statis-
tical signiﬁcant outcome.
Therefore, the present study investigated the expression of
claudin-1 and CD56 separately and in combination in PTC, sol-
itary thyroid nodules with follicular pattern, as well as normal
thyroid tissue. Our aim was to identify the possible diagnostic
role of these two markers in the follicular morphological
mimics.
Materials and methods
The material of this retrospective study included 86 specimens
of surgically removed, formalin-ﬁxed and parafﬁn embedded
thyroid lesions that were received at the pathology department
of Ain Shams University Hospital during the period from
January 2009 to January 2011. All specimens with residualadequate tissue that would allow proper immunohistochemical
assessment of the markers under research were included.
Furthermore, another 10 samples of randomly chosen nor-
mal thyroid tissue obtained from radical laryngectomies for
laryngeal squamous cell carcinomas were included to assess
basic expression of the two markers under investigation in
non lesional thyroid tissue.
Our 86 selected thyroid lesions included:
(a) 29 PTC cases.
(b) 47 cases of solitary follicular patterned nodules.
(c) 10 cases of well differentiated tumors of unknown malig-
nant potential (WDTs-UMP).
The 29 PTC cases were further classiﬁed into 13 cases of
classic PTC and 16 cases of FVPCs.
The 47 cases of solitary follicular patterned nodules in-
cluded 32 cases of hyperplastic nodules, 12 cases of follicular
adenomas, and 3 cases of follicular tumors of unknown malig-
nant potential (FTs-UMP).
Conﬁrmation of the original diagnosis was achieved through
separate revision of H&E stained slides by the two authors inde-
pendently using the well established diagnostic criteria for each
lesion. For the diagnosis of PTC we followed the histological
criteria proposed by Chan [20] which are divided into major
and minor features. The major features include: (1) nuclei are
ovoid rather than rounded; (2) nuclei are crowded, often man-
ifesting as a lack of polarization in the cells that line the follicle;
(3) nuclei show a clear or pale chromatin pattern; (4) psam-
moma bodies are found. If one of the four features was lacking,
four ormore of the following featuresmay occur: (1) presence of
abortive papillae; (2) predominantly elongated or irregular
shaped follicles; (3) dark staining colloid; (4) presence of rare
nuclear pseudoinclusions; or (5) multinucleated histiocytes in
follicle lumen. The term FT-UMP was proposed for encapsu-
lated tumors composed of well differentiated follicular cells
with questionable or incomplete capsular invasion in absence
of PTC type nuclear changes. This term has been used by some
authors to designate follicular carcinoma exhibiting only mini-
mal capsular invasion (irregular capsular proﬁle, with initial
penetration by the tumor which never reached full thickness)
[21]. Follicular adenomas were deﬁned as completely encapsu-
lated follicular tumors with homogenous morphology, lacking
the nuclear features of papillary carcinoma and without capsu-
lar or vascular invasion. While the term WDT-UMP was
proposed for an encapsulated tumor composed of well differen-
tiated follicular cells with questionable PTC type nuclear
changes and shows absent or questionable capsular invasion
[21]. In our study, the WDT-UMP cases showed follicular cells
with some degree of PTC nuclear changes in the form of occa-
sional optically clear nuclei, nuclear grooves and pseudoinclu-
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vascular invasion. There was no controversy regarding the re-
vised diagnoses among both reviewers.
Immunohistochemistry
All 96 samples (86 thyroid lesions and 10 normal thyroid tis-
sues) were subjected to immunohistochemical staining with
claudin-1 and CD56 antibodies. The parafﬁn embedded tissue
sections were deparafﬁnized in xylene and rehydrated through
absolute alcohol. Antigen retrieval in citrate buffer (pH9 Lab
vision cat#AP9003) was used after the sections were treated
in a microwave at 8 w for 5–6 min, then at 3 w for 10 min,
the sections were then left to cool for 20 min. Peroxidase and
protein block were done. After that the slides were incubated
overnight with each of the primary antibodies at room temper-
ature using CD56 antibody (mouse monoclonal antibody 7 ml,
Cat# MS-204-R7 Lab vision corporation, CA, USA) and clau-
din-1 rabbit polyclonal antibody 7 ml, Cat# 359A-18. Cell
marque, CA, USA), followed by rinsing in PBS (pH 7.6). This
was followed by the secondary biotin conjugated antibody for
1 h and ﬁnally the peroxidase conjugated streptavidin for an-
other hour. Diaminbenzidine tetrachloride (DAB) (freshly pre-
pared) was added for 25 min, then counterstained in Harris
Hematoxylin, followed by dehydration, clearing and mount-
ing. Positive control for CD56 antibody was neuroblastoma
while positive control for claudin-1 was normal skin. Negative
controls were done by excluding the primary antibody and its
replacement with a non-immune antibody.
Interpretation of immnohistochemical staining of CD56
The results of immnohistochemical staining were assessed by
both authors and a consensus regarding controversial cases
was reached at a multiheaded microscope.
According to Park et al. [22], strong and complete membra-
nous expression with or without cytoplasmic staining of the
cells qualiﬁed the case as positive for CD56.
Results were expressed in a semiquantitative manner with
respect to the percentage of positive tumor cells: 0, staining in
<10% of the cells; 1, staining in 10–25% of the cells; 2, staining
in 26–50% of the cells; 3, staining in >50% of the cells.
Interpretation of immnohistochemical staining of claudin-1
According to Nemeth et al. [23], cases exhibiting membranous
claudin-1 staining in >5% of the cells were considered posi-
tive. Claudin-1 expression was scored as follows: 0, staining
in <5% of the cells; 1, staining in 5–25% of the cells; 2, stain-
ing in 26–50% of the cells; 3, staining in >50% of the cells.
Statistical analysis
Data were analyzed using the SPSS program Version 15.
Qualitative data were presented using the frequency and re-
lated percentage. Comparison of qualitative variables between
groups was done using the Chi-square or the Exact test. Sensi-
tivity, speciﬁcity, predictive value positive and predictive value
negative were calculated for the examined markers.
Percentage of agreement was done using the Kappa statistic
(K).
A ‘‘P’’ value of 0.05 was chosen as the level of signiﬁcance.The K value can be interpreted as follows (Altman, 1991):
Value of K Strength of agreement
<0.20 Poor
0.21–0.40 Fair
0.41–0.60 Moderate
0.61–0.80 Good
0.81–1.00 Very goodLiterature
Altman (1991) practical statistics for medical research. Lon-
don: Chapman and Hall.
Results
CD56 and claudin-1 expressions in normal thyroid tissue
CD56 positive expression was found in the 10 samples of
normal thyroid tissue 10/10 (100%), which showed strong
membranous CD56 expression in >50% of the cells (score3).
Meanwhile negative claudin-1 expression was observed in the
10 normal thyroid tissue samples (10/10) (100%).
CD56 in the studied thyroid lesions
Among the solitary follicular patterned thyroid nodules; posi-
tive CD56 expression was observed in 42 out of 47 cases
(89.4%) (Table 1), which included 11 out of 12 cases of follic-
ular adenomas (91.7%) (Fig. 1a), 28 out of 32 cases of hyper-
plastic nodules (87.5%) (Fig. 2a) and 3 out of 3 cases of FTs-
UMP (100%) (Fig. 3). All of the positive cases displayed strong
CD56 expression in >50% of the cells (score 3), while the 5
negative cases showed CD56 expression in <10% of the cells.
On the other hand, assessment of CD56 staining in the 29
PTC cases showed negative CD56 expression in 24 out of the
29 cases (82.8%). These cases included 11 out of 13 cases of
classic PTC (84.6%) and 13 out of 16 cases of FVPC
(81.3%) (Fig. 4d). Positive CD56 expression was observed in
only 5 cases of PTC (17.2%); two of which were classic PTC
showing focal expression in 26–50% of the tumor cells (score
2), the other 3 cases were FVPCs and revealed focal expression
in 10–25% of the tumor cells (score 1). No statistical signiﬁ-
cant difference was found between classic PTCs and FVPCs
as regards CD56 expression (P= 1).
CD56 distinguished FVPCs from other follicular patterned
nodules (follicular adenomas, hyperplastic nodules and
FTs-UMP) with a high statistically signiﬁcant difference
(P< 0.001) (Table 1).
Claudin-1 in the studied thyroid lesions
In contrast to CD56, the solitary follicular patterned nodules
showed negative claudin-1 expression (staining in <5% of
the cells) in 38 out of 47 cases (80.9%) (Table 2), which
included 9 out of 12 cases of follicular adenomas (75%)
(Fig. 1b), 27 out of 32 cases of hyperplastic nodules (84.4%)
(Fig. 2b) and 2 out of 3 cases of FTs-UMP (66.7%). Positive
claudin-1 expression was observed in only 9 cases (19.1%).
Five out of these 9 cases showed claudin-1 positivity in
Table 1 Comparison between follicular variant of papillary carcinomas (FVPCs) and other solitary follicular patterned nodules as
regards CD56 expression.
Follicular patterned
thyroid nodules
FVPC Total P value
CD56
Negative
Count 5 13 18 P< 0.001*
K= 0.442% within diagnosis 10.6% 81.3% 28.6%
Positive
Count 42 3 45
% within diagnosis 89.4% 18.7% 71.4%
Total 47 16 63
K: Kappa agreement = 0.442 (moderate strength of agreement).
* Highly signiﬁcant.
Figure 1 (a) Follicular adenoma showing diffuse positive CD56
immunostaining (CD56 · 400). (b) Follicular adenoma showing
negative claudin-1 immunostaining (claudin-1 · 200).
Figure 2 (a) Hyperplastic nodule showing positive CD56
expression (CD56 · 400). (b) Hyperplastic nodule showing nega-
tive claudin-1 expression (claudin-1 · 200).
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nodules and 3 were follicular adenomas. Whereas 4 of the clau-
din-1 positive cases showed focal expression in 5–25% of the
cells (score 1) and these comprised 3 cases of hyperplastic nod-
ules and 1 case of FT-UMP.Meanwhile regarding the 29 PTC cases, strong and dif-
fuse claudin-1 expression in 80–90% of the tumor cells
(score 3) was observed in all cases, including 13/13
cases of classic PTC (Fig. 4a) and 16/16 cases of FVPCs
(Fig. 4c).
Figure 3 Positive CD56 expression in follicular tumor of
unknown malignant potential (CD56 · 100).
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FVPCs and other follicular patterned nodules as regards clau-
din-1 expression (P< 0.001) (Table 2).Figure 4 (a) Classic papillary thyroid carcinoma showing strong dif
Follicular variant of papillary carcinoma (HE · 400). (c) Follicular vari
immunostaining (claudin-1 · 200). (d) Follicular variant of papillary cResults of immunohistochemical expression of (claudin-
1+/CD56) panel in the studied thyroid lesions
(Claudin-1+ve/CD56) expression panel was expressed only
in 13 out of 16 cases (81.3%) of FVPCs. On the other hand,
it was absent in all 47 cases of follicular patterned nodules
(100%). There was a statistically signiﬁcant difference between
FVPC cases and other solitary follicular patterned thyroid nod-
ules as regards the expression of (claudin-1+/CD56) panel
(P< 0.001) (Table 3).
Diagnostic validity of CD56, claudin-1 and (claudin-1+/
CD56) panel
CD56 was 81.3% sensitive and 89.4% speciﬁc in distinguishing
FVPCs from other solitary follicular nodules, in comparison to
claudin-1 which was 100% sensitive and 80.9% speciﬁc.
Although not signiﬁcant, the sensitivity of claudin-1 was higher
than that of CD56, whereas its speciﬁcity was lower than that of
CD56. The immunohistochemical panel of (claudin-1+/
CD56) distinguished FVPCs with diagnostic accuracy of
95.2% and speciﬁcity of 100%which were the highest compared
to those yielded by CD56 and claudin-1 individual expression
(Table 4).fuse membranous claudin-1 immunostaining (claudin-1 · 400). (b)
ant of papillary carcinoma showing diffuse membranous claudin-1
arcinoma showing negative CD56 immunostaining (CD56 · 400).
Table 2 Comparison between FVPCs and solitary follicular patterned nodules as regards claudin-1expression.
Follicular patterned
nodules
FVPC Total P value
Claudin-1
Negative
Count 38 0 38 P< 0.001*
K= 0.682% within diagnosis 80.9% 0% 60.3%
Positive
Count 9 16 25
% within diagnosis 19.1% 100% 39.7%
Total 47 16 63
K: Kappa agreement = 0.682 (good strength of agreement).
* Highly signiﬁcant.
Table 3 Comparison between FVPCs and other solitary follicular patterned nodules as regards (claudin-1+/CD56) expression.
Follicular patterned nodules FVPC Total P value
Antibody
Absent
Count 47 3 50 P< 0.001*
K= 0.866% within diagnosis 100% 18.7% 79.4%
Claudin1+/CD56
Present
Count 0 13 13
% within diagnosis 0 81.3% 20.6%
Total 47 16 63
K: Kappa agreement = 0.866 (very good strength of agreement).
* Highly signiﬁcant.
Table 4 The sensitivity, speciﬁcity, positive predictive value, negative predictive values and accuracy for distinguishing FVPCs from
the other solitary follicular patterned nodules.*
Antibody Sensitivity Speciﬁcity PPV NPV Accuracy
CD56ve 81.3%
(57–93.4)
89.4%
(77.4–95.4)
72.2%
(49–87.5)
93.3%
(82–98)
(13 + 42)/63 = 87.3%
(77–93)
Claudin-1+ve 100%
(80.6–100)
80.9%
(67.4–89.6)
64%
(45–80)
100%
(91–100)
(38 + 16)/63 = 85.7%
(75–92)
Claudin-1+/CD56 81.3%
(57–93.4)
100%
(92.4–100)
100%
(77–100)
94%
(84–98)
(47 + 13)/63 = 95.2%
(87–98)
PPV: positive predictive value, NPV: negative predictive value.
* Estimated measurements 95% conﬁdence interval.
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tiated tumors of unknown malignant potential (WDTs-UMP)
In the light of the previous results, ten cases of WDTs-
UMP were then subjected to immunostaining using CD56
and claudin-1, where 3 out of 10 cases (30%) showed
strong positive CD56 immunoreactivity in 26–50% of the
cells (score 2) and the remaining 7 cases (70%) were
CD56 negative.
Eight cases of WDTs-UMP (80%) showed strong positive
claudin-1 expression in 80–90% of the cells (score 3) while 2
cases (20%) showed negative claudin-1 expression.The results of combined expression of CD56 and claudin-1
in the 10 cases of WDTs-UMP showed: 2 cases (20%) negative
for both claudin-1 and CD56 (claudin-1/CD56), 3 cases
(30%) positive for both claudin-1 and CD56 (claudin-
1+/CD56+) and 5 cases (50%) expressing the (claudin-
1+/CD56) panel (Fig. 5b and c).
Discussion
The diagnosis of PTC is, usually but not always, easily
achieved with almost minimal interobserver variability.
However, in the absence of papillary architecture, distin-
Figure 5 (a) Well differentiated tumor of unknown malignant potential showing some optically clear nuclei, nuclear grooves and nuclear
pseudoinclusions, (HE · 400). (b) The same previous case showing positive claudin-1 expression (claudin-1 · 400). (c) The same case
showing negative CD56 expression (CD56 · 400).
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be challenging [24]. Therefore this study investigated the
possible role of CD56 and claudin-1 in resolving such
problem.
CD56 has been reported to be an antigen related to the dif-
ferentiation of the follicular epithelium [25] and many previous
studies reported high CD56 expression in normal thyroid
tissue and benign thyroid follicular lesions as follicular adeno-
mas and nodular hyperplasias [3,18,22,26–28]
In accordance with those studies, we currently reported a
high positive CD56 expression in normal thyroid tissue com-
pared to PTC cases. The present study also conﬁrmed the
strong and diffuse positive CD56 expression in 89.4% of the
solitary follicular patterned thyroid nodules (Follicular adeno-
mas, FTs-UMP and hyperplastic nodules).
On the other hand, the current study showed negative
CD56 expression in 82.8% of all PTC cases. Similarly, previ-
ous studies reported negative CD56 expression in all or most
of their studied PTC cases [3,16–18,22,27,28].
The underlying molecular context of CD56 expression in
thyroid cancer remains to be elucidated. However it is spec-
ulated that CD56 expression might be involved in the activa-
tion of epithelial mesenchymal transition (EMT) (which
leads to more migratory and invasive cancers), and modula-
tion of genes regulating metastasis as the vascular endothe-lial growth factor (VEGF) [29–32]. This could explain the
maintained elevated CD56 expression in some PTC cases
which may acquire later a more aggressive and metastatic
phenotype.
Based on the previously mentioned results and in the light
of our ﬁnding that there was no statistically signiﬁcant differ-
ence between CD56 expression in FVPCs and its expression in
classic PTCs (P> 0.05), we investigated the applicability of
using CD56 as a marker to differentiate between FVPCs and
other solitary follicular nodules. As a result a statistically sig-
niﬁcant difference between these two groups as regards CD56
expression was found (P< 0.001). Therefore we were able to
emphasize that lack of CD56 expression in the FVPCs was
very helpful in their discrimination from other follicular nod-
ules. The sensitivity and speciﬁcity of CD56 as a negative mar-
ker of FVPCs was 81.3% and 89.4% respectively and its
diagnostic accuracy was 87.3%. On the other hand, Etem el
al. [33] found no statistically signiﬁcant difference between
his studied group of FVPCs and the other group of follicular
tumors (FTs-UMP, follicular adenomas and follicular carcino-
mas) as regards CD56 expression.
In addition to CD56, claudin-1 immunohistochemistry was
previously evaluated in various thyroid lesions [34].
The role of caludin-1 as a tight junction protein in cancer
initiation and progression has been intensively investigated.
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tion of tight junction proteins have been reported in various
human malignancies and are variably associated with tumor
differentiation and survival [35–41]. The overexpression of
these proteins in cancers (which typically lose their tight
junctions) is unexpected but may be related to roles that are
unrelated to tight junction formation [42].
The upstream signaling pathways inﬂuencing claudin-1
expression in thyroid tumors remain elusive. Tzelepi et al.
[34] demonstrated that papillary carcinoma being a well
differentiated thyroid carcinoma shows high claudin-1 expres-
sion, and that dedifferentiation of thyroid tumors involves
tight junction impairment via claudin-1 down regulation. In
addition, loss of tight junction integrity leads to an increased
inﬂux of growth factors, nutrients and other tumor promot-
ing molecules, therefore providing an advantage for tumor
development and progression. On the other hand, Hucz et
al. [12] and Nemeth et al. [23] associated claudin-1 expression
with the invasive and metastatic phenotype of PTC due to
preserved claudin-1 strong expression in the lymph node
metastasis.
In the current study all cases of PTCs (100%) showed
strong and diffuse claudin-1 expression .While all normal thy-
roid tissue samples (100%) and 80.9% of the solitary follicular
patterned nodules showed negative claudin-1 expression. Sim-
ilar results were elucidated by Hucz et al. [12] and Nemeth et
al. [23] who reported high claudin-1 expression in PTC cases
compared to negative expression in normal thyroid tissue
and in follicular adenomas. This differential expression in the
normal versus neoplastic tissues may provide new opportuni-
ties for targeted cancer therapy [42]. In addition, our results
showed a high statistically signiﬁcant difference between
FVPCs and other solitary follicular patterned nodules as re-
gards claudin-1 expression (P< 0.001). Thus claudin-1 immu-
nohistochemistry is proved to be very useful in differentiating
FVPCs from other follicular nodules with 100% sensitivity
and 80.9% speciﬁcity, 100% NPV and 85.7% diagnostic accu-
racy. Although the speciﬁcity of claudin-1 is lowered compared
to that of CD56, claudin-1 negative expression can rule out the
possibility of papillary carcinoma in any suspicious follicular
nodule.
Our recent observations encouraged us to assess the possi-
ble value of the (claudin-1+/CD56) panel in the differential
diagnosis of the studied thyroid nodules with a better statisti-
cal signiﬁcant outcome. As a result the sensitivity and NPV of
(claudin-1+/CD56) combination were lowered compared to
those of claudin-1 alone. However this panel was able to dis-
criminate FVPCs among other follicular patterned nodules
with diagnostic accuracy (95.2%), speciﬁcity (100%), and
PPV (100%), which were the highest compared to those of
CD56 and claudin-1+. Therefore adding CD56 to claudin-
1 especially in claudin-1 positive cases could greatly aid in
reaching the ﬁnal diagnosis.
Based on the previous results of CD56 and claudin-1 immu-
noreactivities in our studied cases, this work proposed the fol-
lowing protocol in the evaluation of the follicular thyroid
nodules:
(a) Diagnosis of papillary carcinoma (FVPC) in any contro-
versial case should be deﬁnitely excluded if it shows neg-
ative claudin-1 expression (claudin-1 sensitivity is 100%
and its NPV is 100%).(b) Diagnosis of papillary carcinoma (FVPC) is deﬁnite in
any controversial case if it shows (claudin-1+/CD56)
immunoreactivity (this panel has 100% speciﬁcity and
100% PPV).
(c) The diagnosis of PTC (FVPC) is excluded by 94% in any
controversial case if it shows (claudin-1+/CD56+)
panel [NPV of (claudin-1+/CD56) is 94%].
Williams et al. [21] have proposed the term WDT-UMP for
an encapsulated tumor composed of well differentiated follicu-
lar cells with questionable PTC type nuclear changes, whether
capsular invasion is absent or questionable and in absence of
vascular invasion. The problem with this term is that it doesn’t
really solve the interobserver variability between pathologists
regarding the diagnosis of FVPC. Instead it allows safe expres-
sion of differences in opinion and help in avoiding excessive
treatment in controversial cases that cannot be readily placed
in a deﬁnite benign or a deﬁnite malignant category.
Therefore the application of the above mentioned protocol
on the atypical category of WDTs-UMP might be helpful in
the reclassiﬁcation and interpretation of the biologic behavior
of these tumors.
Accordingly, by evaluating the claudin-1 and CD56 immu-
noreactivities in the 10 studied cases of WDTs-UMP, the
diagnosis of papillary carcinoma was likely to be excluded
in the two cases which showed negative claudin-1 expression.
Moreover, the diagnosis of papillary carcinoma would prob-
ably be excluded by 94% in the 3 cases which showed (clau-
din-1+/CD56+) panel. Hence we could suggest that the
focal and incompletely developed PTC nuclear changes ob-
served in these cases may be due to a mere artifact of ﬁxa-
tion. On the other hand, the diagnosis of papillary
carcinoma could be suggested in the 5 cases which showed
(claudin-1+/CD56) panel.
The more apparent nuclear pseudoinclusions and grooves
seen in these 5 cases may prove to be the expression of a path-
ological abnormality rather than a technical error. In this sit-
uation the nuclear features argue in favor of rediagnosis of
the (claudin-1+/CD56+) cases as PTC or at least suggest a
link between WDT-UMP and PTC as the former may possibly
be a precursor of the latter.
In conclusion, although the differential diagnoses of thy-
roid follicular nodules are based on histologic and cytomor-
phologic criteria, combined utility CD56 and caludin-
1(claudin1+/CD56) might be useful in the diagnosis of
PTC. However a question is raised ‘‘Does (claudin-1+/
CD56+) expression panel has a practical diagnostic role in
the sense of absolute pushing of the WDT-UMP cases into
the benign category?’’ Our study demonstrated that this could
be achieved by 94%. However the satisfactory answer to this
question will require long term follow up in order to see
whether the biologic effects of malignancy will inﬂuence these
cases or not. Therefore the current study recommends the eval-
uation of the role of claudin-1 and CD56 panel in more exten-
sive studies including other variants of follicular cell derived
nodules especially the borderline category of WDT-UMP to
evaluate their expected behavior.Competing interests
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